Advertisement

Anti-Anaphylactic Properties of BN 52021: A Potent Platelet Activating Factor Antagonist

  • P. Braquet
  • R. H. Bourgain
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 215)

Abstract

PAF-acether is a potential mediator of anaphylaxis and inflammatory reactions (Benveniste, Henson and Cochrane, 1972). It is released by various immune and chemical stimuli from inflammatory cells (basophils, neutrophils, eosinophils, macrophages, platelets) as well as from vascular endothelium; PAF-acether increases vascular permeability and causes sustained hypotension and thrombosis (reviewed by Braquet et al., 1986; Vargaftig and Braquet, 1987). It may also participate in various hypersensitivity reactions including bronchial asthma which cannot be fully accounted for by the known inflammatory mediators, including peptido-leukotrienes (reviewed by Vargaftig et al., 1985).

Keywords

Platelet Activate Factor Perfuse Lung Glyceryl Ether Human Eosinophil Major Basic Protein 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Adnot, S., Lefort, J., Lagente, V., Braquet, P. and Vargaftig, B.B. (1986). Interference of BN 52021, a PAF-acether antagonist, with endotoxin-induced hypotension in the guinea-pig. Pharmac. Res. Commun. 18 (Suppl.), 197CrossRefGoogle Scholar
  2. Arnoux, B., Duval, D. and Benveniste, J. (1980). Release of platelet-activating factor (PAF-acether) from alveolar macrophages by the calcium ionophore A23187 and phagocytosis. Eur. J. Clin. Invest. 10, 437CrossRefGoogle Scholar
  3. Arnoux, B. and Gillis, C.N. (1986). Role of fatty acids and BN 52021 on vascular and airway actions of platelet-activating factor (PAF) in isolated rabbit lung in situ. Bull. Eur. Physiopath. Resp. 22 (Suppl.), 51Google Scholar
  4. Baggiolini, M. and Dewald, B. (1986). Stimulus amplification by PAF and LTB4 in human neutrophils. Pharmac. Res. Commun. 18 (Suppl.), 51CrossRefGoogle Scholar
  5. Baranes, J., Hellegouarch, A., Le Hegarat, M., Viossat, I., Auguet, M., Chabrier, P.E., Clostre, F. and Braquet, P. (1986). The effects of PAF-acether on the cardiovascular system and their inhibition by a new highly specific PAF-acether receptor antagonist BN 52021. Pharmac. Res. Commun. 18, 737CrossRefGoogle Scholar
  6. Barner, R., Hadvary, P., Burri, K., Hirth, G., Cassai, J.M. and Muller, K. (1985). Glycerin derivatives. Eur. Pat. Appl. EP 147,768 12.18.84 [see Chem. Abstracts 104, 88939n, (1986)].Google Scholar
  7. Barner, R., Hadvary, P., Burri, K., Hirth, G., Cassai, J.M. and Muller, K. (1985). Glycerin derivatives. Eur. Pat. Appl. EP 147,768 12.18.84 [see Chem. Abstracts 104, 88939n, (1986)].Google Scholar
  8. Barnes, P.J., Cuss, F.M. and Palmer, J.B. (1985). The effect of airway epithelium on smooth muscle contractility in bovine trachea. Br. J. Pharmac. 86, 685CrossRefGoogle Scholar
  9. Barnes, P.J., Cuss, F.M. and Palmer, J.B. (1985). The effect of airway epithelium on smooth muscle contractility in bovine trachea. Br. J. Pharmac. 86, 685CrossRefGoogle Scholar
  10. Barnes, P.J., Cuss, F.M. and Palmer, J.B. (1985). The effect of airway epithelium on smooth muscle contractility in bovine trachea. Br. J. Pharmac. 86, 685CrossRefGoogle Scholar
  11. Benveniste, J., Henson, P.M. and Cochrane, C.G. (1972). Leukocyte-dependent histamine release from rabbit platelets. The role of IgE, basophils, and a platelet-activating factor. J. Exp. Med. 136, 1356CrossRefGoogle Scholar
  12. Berti, F., Omini, C., Rossoni, G. and Braquet, P. (1986). Protection by two ginkgolides, BN 52020 and BN 52021, against guinea-pig lung anaphylaxis. Pharmac. Res. Commun. 18, 775CrossRefGoogle Scholar
  13. Borgeat, P., Fruteau de Laclos, B., Rabinovitch, H., Picard, S., Braquet, P., Hebert,J. and Laviolette, M. (1984). Eosinophil-rich human polymorphonuclear leukocyte preparations characteristically release leukotriene C4 on ionophore A 23187 challenge. J. Allergy Clin. Immunol. 74, 310CrossRefGoogle Scholar
  14. Boukili, M.A., Lagente, V., Lefort, J. and Vargaftig, B.B. (1985). Bronchoconstriction by f-met-leu-phe may involve cyclooxygenase and leukotriene-independent mechanisms. Int. J. Immunopharmac. 7, 382CrossRefGoogle Scholar
  15. Bourgain, R.H., Maes, L., Braquet, P. Andries, R., Touqui, L. and Braquet, M. (1985). The effect of 1–0-alkyl-2-acetyl-sn-glycero3-phosphocholine (PAF-acether) on the arterial wall. Prostaglandins, 30, 185CrossRefGoogle Scholar
  16. Braquet, P. (1984). Treatment or prevention of disorders provoked by factor acether, GB Patent, 84/18, 424 (July 19, 1984) Belg. BE 901, 915 [see Chem. Abstracts 103, 189808d, 1985].Google Scholar
  17. Braquet, P., Spinnewyn, B., Braquet, M., Bourgain, R.H., Taylor, J.E., Etienne, A. and Drieu, K. (1985a). BN 52021 and related compounds: a new series of highly specific PAF-acether receptor antagonists isolated from Ginkgo biloba. Blood and Vessels, 16, 559Google Scholar
  18. Braquet, P., Etienne, A., Touvay, C., Bourgain, R.H., Lefort, J. and Vargaftig, B.B. (1985b). Involvement of platelet activating factor in respiratory anaphylaxis, demonstrated by PAF-acether inhibitor BN 52021. Lancet, I, 1501Google Scholar
  19. Braquet, P. and Godfroid, J.J. (1986). PAF-acether specific binding sites: 2. Design of specific antagonists. TIPS 7, 397Google Scholar
  20. Braquet, P., Drieu, K. and Etienne, A. (1986). Le Ginkgolide B (BN 52021) un puissant inhibiteur du PAF-acether isole du Ginkgo biloba L. Actualites de Chimie Therapeutique (Paris) 13, 237Google Scholar
  21. Braquet, P., Drieu, K. and Etienne, A. (1986). Le Ginkgolide B (BN 52021) un puissant inhibiteur du PAF-acether isole du Ginkgo biloba L. Actualites de Chimie Therapeutique (Paris) 13, 237Google Scholar
  22. Braquet, P.. Etienne, A., Mencia-Huerta, J.M. and Clostre, F. (1987). The role of platelet activating factor in gastrointestinal ulcerations. Eur. J. Pharmac. (submitted).Google Scholar
  23. Braquet, P.. Etienne, A., Mencia-Huerta, J.M. and Clostre, F. (1987). The role of platelet activating factor in gastrointestinal ulcerations. Eur. J. Pharmac. (submitted).Google Scholar
  24. Bruynzeel, P.L.B., Koenderman, L., Kok, P.T.M., Hameling, M.L. and Verhagen, J. (1986). Platelet-activating factor (PAF-acether)-induced leukotriene C4 formation and luminol dependent chemiluminescence by human eosinophils. Pharmac. Res. Commun. 18, 61CrossRefGoogle Scholar
  25. Bruynzeel, P.L.B., Koenderman, L., Kok, P.T.M., Hameling, M.L. and Verhagen, J. (1986). Platelet-activating factor (PAF-acether)-induced leukotriene C4 formation and luminol dependent chemiluminescence by human eosinophils. Pharmac. Res. Commun. 18, 61CrossRefGoogle Scholar
  26. Bruynzeel, P.L.B., Koenderman, L., Kok, P.T.M., Hameling, M.L. and Verhagen, J. (1986). Platelet-activating factor (PAF-acether)-induced leukotriene C4 formation and luminol dependent chemiluminescence by human eosinophils. Pharmac. Res. Commun. 18, 61CrossRefGoogle Scholar
  27. Cirino, M., Lagente, V., Lefort, J. and Vargaftig, B.B. (1986). A study with BN 52021 demonstrates the involvement of PAF-acether in IgE-dependent anaphylactic bronchoconstriction. Prostaglandins, 32, 121CrossRefGoogle Scholar
  28. Cirino, M., Lagente, V., Lefort, J. and Vargaftig, B.B. (1986). A study with BN 52021 demonstrates the involvement of PAF-acether in IgE-dependent anaphylactic bronchoconstriction. Prostaglandins, 32, 121CrossRefGoogle Scholar
  29. Cirino, M., Lagente, V., Lefort, J. and Vargaftig, B.B. (1986). A study with BN 52021 demonstrates the involvement of PAF-acether in IgE-dependent anaphylactic bronchoconstriction. Prostaglandins, 32, 121CrossRefGoogle Scholar
  30. Cirino, M., Lagente, V., Lefort, J. and Vargaftig, B.B. (1986). A study with BN 52021 demonstrates the involvement of PAF-acether in IgE-dependent anaphylactic bronchoconstriction. Prostaglandins, 32, 121CrossRefGoogle Scholar
  31. Cuss, F.M., Dixon, C.M. and Barnes, P.J. (1986). Effects of inhaled platelet activating factor on pulmonary function and bronchial responsiveness in man. Lancet, II, 189Google Scholar
  32. Darius, H., Lefer, D.J., Smith, J.B. and Lefer, A.M. (1986). Role of platelet-activating factor-acether in mediating guinea-pig anaphylaxis. Science, 232, 58CrossRefGoogle Scholar
  33. De Monchy, J.G., Kauffman, H.F., Vense, P., Koeter, G.H., Jansen, H.M., Sluiter, H.J. and De Vries, K. (1985). Bronchoalveolar eosinophilia during allergen-induced late asthmatic reactions. Am. Rev. Respir. Dis. 135, 373Google Scholar
  34. Desquand, S., Touvay, C., Randon, J., Lagente, V., Vilain, B., Maridonneau-Parini, I., Etienne, A., Lefort, J., Braquet, P. and Vargaftig, B.B. (1986). Interference of BN 52021 (Ginkgolide B) with the bronchopulmonary effects of PAF-acether in the guinea-pig. Eur. J. Pharmac. 127, 83CrossRefGoogle Scholar
  35. Detsouli, A., Lefort, J. and Vargaftig, B.B. (1985). Histamine and leukotriene-independent guinea-pig anaphylactic shock unaccounted for by PAF-acether. Br. J. Pharmac. 84, 801CrossRefGoogle Scholar
  36. Detsouli, A., Lefort, J. and Vargaftig, B.B. (1985). Histamine and leukotriene-independent guinea-pig anaphylactic shock unaccounted for by PAF-acether. Br. J. Pharmac. 84, 801CrossRefGoogle Scholar
  37. Detsouli, A., Lefort, J. and Vargaftig, B.B. (1985). Histamine and leukotriene-independent guinea-pig anaphylactic shock unaccounted for by PAF-acether. Br. J. Pharmac. 84, 801CrossRefGoogle Scholar
  38. Etienne, A., Hecquet, F., Soulard, C., Spinnewyn, B., Clostre, F. and Braquet, P. (1985). In vivo inhibition of plasma protein leakage and salmonella enteritidis-induced mortality in the rat by a specific PAF-acether antagonist: BN 52021. Agents and Actions, 17, 368CrossRefGoogle Scholar
  39. Etienne, A., Hecquet, F., Soulard, C., Spinnewyn, B., Clostre, F. and Braquet, P. (1985). In vivo inhibition of plasma protein leakage and salmonella enteritidis-induced mortality in the rat by a specific PAF-acether antagonist: BN 52021. Agents and Actions, 17, 368CrossRefGoogle Scholar
  40. Filley, W.V., Kephart, G.M., Holley, K.E. and Gleich, G.J. (1982). Identification by immunofluorescence of eosinophil granule major basic protein in lung tissues of patients with bronchial asthma. Lancet, II, 11Google Scholar
  41. Fink, A., Afek, A., Shalev, Y., Eliraz, A. and Bentwich, Z. (1986). The sensitivity of peripheral blood leukocytes of ischemic heart patients to PAF-acether and cysteinyl containing leukotrienes: determination by the tube leukocyte adherence inhibition assay. 6th Int. Conference on Prostaglandins and related Compounds, Florence, Italy, June 3–6, Abst. p. 301Google Scholar
  42. Fitzgerald, M.F., Moncada, S. and Parente, L. (1986). The anaphylactic release of platelet-activating factor from perfused guinea-pig lungs. Br. J. Pharmac. 88, 149CrossRefGoogle Scholar
  43. Foegh, M., Alijani, M.R., Helfrich, G.B., Khirabadi, B.S. and Ramwell, P. (1985). Prolongation of cardiac allograft survival with the PAY antagonist BN 52021 and with the thromboxane receptor antagonists L640035 and L636499. Advances in Prostaglandin, Thromboxane and Leukotriene Research, 15, 381Google Scholar
  44. Foegh, M.L., Khirabadi, B.S., Rowles, J.R. and Ramwell,P.W. (1986). Prolongation of cardiac allograft survival with BN 52021 a specific antagonist of platelet activating factor. Transplantation, 42, 86Google Scholar
  45. Garay, R. and Braquet, P. (1986). Involvement of K+ movements in the membrane signal induced by PAF-acether. Biochem. Pharmac. 35, 2811CrossRefGoogle Scholar
  46. Gleich, G.J., Loegering, D.A., Mann, K.G. and Maldonado, J.E. (1976). Comparative properties of the Charcot-Leyden crystal protein and the major basic protein from human eosinophils. J. Clin. Invest. 57, 633CrossRefGoogle Scholar
  47. Guinot,Ph., Braquet, P., Duchier, J. and Cournot, A. (1986). Inhibition of PAF-acether induced weal and flare reaction in man by a specific PAF-antagonist. Prostaglandins, 32, 160CrossRefGoogle Scholar
  48. Harczy, M., Maclouf, J., Pradelles, P., Braquet, P., Borgeat, P. and Sirois, P. (1986). Inhibitory effects of a novel platelet activating factor (PAF) antagonist (BN 52021) on antigen-induced prostaglandin and thromboxane formation by the guinea-pig lung. Pharmac. Res Commun. 18 (Suppl.), 111CrossRefGoogle Scholar
  49. Harczy, M., Maclouf, J., Pradelles, P., Braquet, P., Borgeat, P. and Sirois, P. (1986). Inhibitory effects of a novel platelet activating factor (PAF) antagonist (BN 52021) on antigen-induced prostaglandin and thromboxane formation by the guinea-pig lung. Pharmac. Res Commun. 18 (Suppl.), 111CrossRefGoogle Scholar
  50. Henocq, E. and Vargaftig, B.B. (1986). Accumulation of eosinophils in response to intracutaneous PAF-acether and allergens in man. Lancet, I, 1378Google Scholar
  51. Hoshikawa-Fujimura, A.Y., Chamone, D.A.F. and Jancar, S. (1986). Effect of BN 52021 on human PMN superoxide anion production. 6th Int. Conference on Prostaglandins and related Compounds, Florence (Italy). June 3–6, Abst. p. 388Google Scholar
  52. Koltai, M., Lepran, I., Szekeres, L., Viossat, I., Chabrier, E. and Braquet, P. (1986). Effect of BN 52021, a specific PAF-acether antagonist, on cardiac anaphylaxis in Langendorff hearts isolated from passively sensitized guinea-pigs. Eur. J. Pharmac. 130, 133CrossRefGoogle Scholar
  53. Kornecki, E., Ehrlich, Y.H. and Lenox, R.H. (1984). factor-induced aggregation of human platelets specifically inhibited by triazolobenzodiazepines. Science, 226, 1454CrossRefGoogle Scholar
  54. Kravis, T.C. and Henson, P.M. (1975). IgE-induced release of platelet activating factor from rabbit lung. J. Immunol. 115, 1677Google Scholar
  55. Kuster, L.J., Filep, J. and Frolich, J.C. (1986). Mechanisms of PAF-induced platelet aggregation in man. Thrombos. Res., 43, 425CrossRefGoogle Scholar
  56. Lachachi, H., Plantavid, M., Simon, M.-F., Chap, H., Braquet, P. and Douste-Blazy, L. (1985). Inhibition of transmembrane movement and metabolism of platelet-activating factor (PAF-acether) by a specific antagonist, BN 52021. Biochem. Biophys. Res. Commun. 132, 460CrossRefGoogle Scholar
  57. Lachachi, H., Plantavid, M., Simon, M.-F., Chap, H., Braquet, P. and Douste-Blazy, L. (1985). Inhibition of transmembrane movement and metabolism of platelet-activating factor (PAF-acether) by a specific antagonist, BN 52021. Biochem. Biophys. Res. Commun. 132, 460CrossRefGoogle Scholar
  58. Lagente, V., Desquand, S., Randon, J., Lefort, J. and Vargaftig, B.B. (1985). Interference of PAF-acether antagonists with the effects of PAF itself and of anaphylactic shock in vitro and in vivo guinea-pig bronchopulmonary preparations. Prostaglandins, 30, 703CrossRefGoogle Scholar
  59. Lagente, V., Desquand, S., Randon, J., Lefort, J. and Vargaftig, B.B. (1985). Interference of PAF-acether antagonists with the effects of PAF itself and of anaphylactic shock in vitro and in vivo guinea-pig bronchopulmonary preparations. Prostaglandins, 30, 703CrossRefGoogle Scholar
  60. Lee, T.C., Lenihan, D.J., Malone, B., Roddy, L.L. and Wasserman, S.I. (1984). Increased biosynthesis of platelet-activating factor in activated human eosinophils. J. Biol. Chem. 259, 5526Google Scholar
  61. Lefort, J., Malanchere, E., Pretolani, M. and Vargaftig, B.B. (1986). Immunisation induces bronchial hyper-reactivity and increased mediator release from guinea-pig lungs. Brit. J. Pharmac. 89, 768 PGoogle Scholar
  62. Lefort, J., Rotilio, D. and Vargaftig, B.B. (1984). The platelet-independent release of thromboxane A2 by PAF-acether from guinea-pig lungs involves mechanisms distinct from those for leukotriene C4 and bradykinin. Br. J. Pharmac. 82, 525CrossRefGoogle Scholar
  63. Lellouch-Tubiana, A., Lefort, J., Pirotzky, E., Vargaftig, B.B. and Pfister, A. (1985). Ultrastructural evidence for extravascular recruitment in the lung upon intravenous injection of platelet-activating factor (PAF-acether) to guinea-pigs. Br. J. Exp. Path. 66, 345Google Scholar
  64. Lellouch-Tubiana, A., Lefort, J., Pirotzky, E., Vargaftig, B.B. and Pfister, A. (1985). Ultrastructural evidence for extravascular recruitment in the lung upon intravenous injection of platelet-activating factor (PAF-acether) to guinea-pigs. Br. J. Exp. Path. 66, 345Google Scholar
  65. MacDonald, A.J., Moqbel, R., Wardlaw, A.J. and Kay, A.B. (1986). Platelet-activating factor (PAF-acether) enhances eosinophil cytotoxicity in vitro. J. Allergy Clin. Immunol. 77, 227Google Scholar
  66. McManus, L.M. and Pinckard, R.N. (1985). Kinetics of acetyl glyceryl ether phosphorylcholine (AGEPC)-induced acute lung alterations in the rabbit. Am. J. Pathol. 121, 55Google Scholar
  67. Maridonneau-Parini, I., Lagente, V., Lefort, J., Randon, J., Russo-Marie, F. and Vargaftig, B.B. (1985). Desensitization to PAF-induced bronchoconstriction and to activation of alveolar macrophages by repeated inhalations of PAF in the guinea-pig. Biochem. Biophys. Res. Commun. 131, 42CrossRefGoogle Scholar
  68. Neuman, I., Inbar, O. and Creter, D. (1984). The kinin system in exercise-induced asthma. Ann. Allergy, 53, 351Google Scholar
  69. Nunez, D., Chignard, M., Korth, R., Le Couedic, J.-P., Norel, X., Spinnewyn, B., Braquet, P. and Benveniste, J. (1986). Specific inhibition of PAF-acether-induced platelet activation by BN 52021 and comparison with the PAF-acether inhibitors Kadsurenone and CV-3988. Eur. J. Pharmac. 123, 197CrossRefGoogle Scholar
  70. Page, C.P., Paul, W., Basran, G.S. and Morley, J. (1985). Platelet activation in asthma. In: Bronchial Asthma: Mechanisms and Therapeutics, Eds Weiss, E.R., Segal, M.S. and Stein, M., Little, Brown and Co., Boston. pp. 266Google Scholar
  71. Parente, N. and Flower, R.J. (1985). Hydrocortisone and macrocortin inhibit the zymosan-induced release of lyso-PAF from rat peritoneal leucocytes. Life Sci. 36, 1225CrossRefGoogle Scholar
  72. Patterson, R. and Harris, K.E. (1983). The activity of aerosolized and intracutaneous synthetic platelet activating factor (AGEPC) in rhesus monkeys with IgE-mediated airway responses and normal monkeys. J. Lab. Clin. Med. 102, 933Google Scholar
  73. Piper, P.J. and Stewart, A. G. (1986). Evidence of a role for factor in antigen-induced coronary vasoconstriction in guinea-pig perfused hearts. Brit. J. Pharmac. 88, 238 PGoogle Scholar
  74. Plante, G.E., Hebert, R.L., Lamoureux, C., Braquet, P. and Sirois, P. (1986). Hemodynamic effects of PAF-acether. Pharmac. Res. Commun. 18 (Suppl.), 173CrossRefGoogle Scholar
  75. Plotkine, M., Massad, L., Allix, M., Capdeville, C. and Boulu, R.G. (1986). Cerebral effects of PAF-acether in rats. 6th Conference on Prostaglandins and related Compounds, Florence (Italy) June 3–6 Abstr. p. 300Google Scholar
  76. Pusa, T. and Tchorzewski, H. (1985). Analysis of proteolytic enzymes and their natural inhibitors in serum and bronchial lavage fluid in atopic bronchial asthma. Allerg. Immunol. 31, 169Google Scholar
  77. Robbins, J.C., MaChoy, B.H., Lam, M.J., Ponpipom, M., Rupprecht, K.M. and Shen, T.Y. A synthetic phospholipid inhibitor of platelet-activating factor (PAF) biosynthesis. Fed. Proc. 44, 1269Google Scholar
  78. Ross, R. and Vogel, A. (1978). The platelet derived growth factor. Cell, 14, 203CrossRefGoogle Scholar
  79. Rotilio, D., Lefort, J., Detsouli, A. and Vargaftig, B.B. (1983). Absence de contribution du PAF-acether a la reponse anaphylactique pulmonaire in vitro chez le cobaye. J. Pharmac. (Paris) 14 (Suppl. 1), 97Google Scholar
  80. Rubin, A.E., Smith, L.J. and Patterson, R. (1986). Effects of platelet activating factor (PAF) on normal human airways. Am. Rev. Resp. Dis. 133, A91Google Scholar
  81. Sanchez-Crespo, M., Fernandez-Gallardo, S., Nieto, M.L., Baranes, J. and Braquet, P. (1985). Inhibition of the vascular actions of IgG aggregates by BN 52021, a highly specific antagonist of PAF-acether. Immunopharmacology, 10, 69CrossRefGoogle Scholar
  82. Shen, T.Y., Hwang, S.B., Chang, M.N., Doebber, T.W., Lam, M.H., Wu, M.S. Wang, X., Han, G.Q. and Li, R.Z. (1985). Characterization of a platelet-activating factor receptor antagonist isolated from haifenteng (Piper futokadsura): specific inhibition of in vitro and in vivo platelet-activating factor-induced effects. Proc. Natl. Acad. Sci. USA 82, 672–676 (see also Patent JP 60 97,972 [85 97, 972] 31 May 1985, US Appl. 541, 806 13 Oct. 1983 ).Google Scholar
  83. Shen, T.Y., Hwang, S.B., Chang, M.N., Doebber, T.W., Lam, M.H., Wu, M.S. Wang, X., Han, G.Q. and Li, R.Z. (1985). Characterization of a platelet-activating factor receptor antagonist isolated from haifenteng (Piper futokadsura): specific inhibition of in vitro and in vivo platelet-activating factor-induced effects. Proc. Natl. Acad. Sci. USA 82, 672–676 (see also Patent JP 60 97,972 [85 97, 972] 31 May 1985, US Appl. 541, 806 13 Oct. 1983 ).Google Scholar
  84. Sirois, P., Harczy, M., Robidoux, C., Borgeat, P. and Braquet, P. (1986). Lipid mediators in lung anaphylaxis. In: Lipid Mediators in Immunology of Burn and Sepsis, a NATO ASI, Helsingor (Denmark) July 20–25, Abst. p. 40Google Scholar
  85. Stanworth, D.R., Griffiths, H.R. and Braquet, P. (1986). Effect of PAF-acether antagonists on pre-formed mediator secretion from mast cells In: 2nd World Conference on Inflammation, Monte Carlo, March 19–22, Abst. A.193Google Scholar
  86. Stenzel, H., Hummer, B. and Hahn, H.L. (1986). Effect of the PAF-antagonist SRI 63–441 on the allergic reaction in awake dogs with natural asthma. Platelets, Analgesics and Asthma, IIIrd. Int. Symposium Davos, Switzerland, Sept. 7–9. Abstr. p. 50Google Scholar
  87. Stenzel, H., Sannwal, U. and Hahn, H.L. (1986). Effect of the PAF-antagonist RP 48740 on allergic reactions in awake dogs. 6th Int. Conference on Prostaglandins, Florence (Italy), June 3–6, Abstr. p. 306Google Scholar
  88. Touvay, C., Etienne, A. and Braquet, P. (1985). Inhibition of antigen-induced lung anaphylaxis in the guinea-pig by BN 52021 a new specific PAF-acether receptor antagonist isolated from Ginkgo biloba. Agents and Actions, 17, 371CrossRefGoogle Scholar
  89. Touvay, C., Etienne, A. and Braquet, P. (1985). Inhibition of antigen-induced lung anaphylaxis in the guinea-pig by BN 52021 a new specific PAF-acether receptor antagonist isolated from Ginkgo biloba. Agents and Actions, 17, 371CrossRefGoogle Scholar
  90. Touvay, C., Etienne, A. and Braquet, P. (1985). Inhibition of antigen-induced lung anaphylaxis in the guinea-pig by BN 52021 a new specific PAF-acether receptor antagonist isolated from Ginkgo biloba. Agents and Actions, 17, 371CrossRefGoogle Scholar
  91. Touvay, C., Vilain, B., Carre, C., Etienne, A. and Braquet, P. (1986c). Comparative effects of three orally active PAF-receptor antagonists extracted from Ginkgo biloba: on in vivo bronchoconstrictions and in vitro lung strips contractions induced by PAF-acether. 6th Conference on Prostaglandins and related Compounds. Florence, Italy, June 3–6, Abstr. p. 316Google Scholar
  92. Vargaftig, B.B., Borgeat, P., Braquet, P., Braquet, M., Brocklehurst, W.E., Dahlen, S.E., Drazen, J.M., Etienne, A., Fitzpatrick, F.A., Henson, P.M., Holgate, S.T., Israel, E., Mencia-Huerta J.M., Murphy, R.C., Robinson, C. and Shore, S. (1985). Leukotrienes and immediate hypersensitivity. Ann. Inst. Pasteur/Immunol. 136D, 175CrossRefGoogle Scholar
  93. Vargaftig, B.B., Borgeat, P., Braquet, P., Braquet, M., Brocklehurst, W.E., Dahlen, S.E., Drazen, J.M., Etienne, A., Fitzpatrick, F.A., Henson, P.M., Holgate, S.T., Israel, E., Mencia-Huerta J.M., Murphy, R.C., Robinson, C. and Shore, S. (1985). Leukotrienes and immediate hypersensitivity. Ann. Inst. Pasteur/Immunol. 136D, 175CrossRefGoogle Scholar
  94. Vercelotti, G.M., Huh, P.W., Yin, H.Q., Nelson, R.D. and Jacob, H.S. (1986). Enhancement of PMN-mediated endothelial damage by platelet activating factor (PAF): PAF primes PMN responses to activating stimuli. 28th. Annual Meeting of the American Society of Hematology (December) Abstr. p. 204Google Scholar
  95. Vilain, B., Lagente, V., Touvay, C., Desquand, S., Randon, J., Lefort, J., Braquet, P. and Vargaftig, B.B. (1986). Pharmacological control of the in vivo passive anaphylactic shock by the PAF-acether antagonist compound BN 52021. Pharmac. Res. Commun. 18 (Suppl.), 119CrossRefGoogle Scholar
  96. Villamediana, L.M., Sanz, E., Fernandez-Gallardo, S., Caramelo, C., Sanchez-Crespo, M., Braquet, P. and Lopes-Novoa, J.M. (1986). Effects of the platelet-activating factor antagonist BN 52021 on the hemodynamics of rats with experimental cirrhosis of the livers. Life Sci., 39, 201CrossRefGoogle Scholar
  97. Villamediana, L.M., Sanz, E., Fernandez-Gallardo, S., Caramelo, C., Sanchez-Crespo, M., Braquet, P. and Lopes-Novoa, J.M. (1986). Effects of the platelet-activating factor antagonist BN 52021 on the hemodynamics of rats with experimental cirrhosis of the livers. Life Sci., 39, 201CrossRefGoogle Scholar
  98. Wardlaw, A.J. and Kay, A.B. (1986). PAF-acether is a potent chemotactic factor for human eosinophils. J. Allergy Clin. Immunol. 77, 236Google Scholar
  99. Wardlaw, A.J. and Kay, A.B. (1986). PAF-acether is a potent chemotactic factor for human eosinophils. J. Allergy Clin. Immunol. 77, 236Google Scholar
  100. Winslow, C.M., Vallespir, S.R., Frisch, G.E., D’Aries, F.J., DeLillo, A.K., Houlihan, W.J., Parrino, V., Schmitt, G. and Saunders, R.N. (1985a). A novel platelet activating factor receptor antagonist. Prostaglandins, 30, 697CrossRefGoogle Scholar
  101. Winslow, C.M., Frisch, G.E., D’Aries, F.J., Handely, D.A., Melden, M.K., Deacon, R.W., Houlihan, W.J., Parrino, V., Schmitt, G. and Saunders, R.N. (1985b). A platelet-activating factor (PAF) receptor antagonist which influences the primary physiological responses of rodents to PAF. Prostaglandins, 30, 698CrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1987

Authors and Affiliations

  • P. Braquet
    • 1
  • R. H. Bourgain
    • 2
  1. 1.I.H.B. Research LaboratoriesLe Plessis RobinsonFrance
  2. 2.Department of Physiology, Medical FacultyVrije Universiteit BrusselBrusselsBelgium

Personalised recommendations